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We read with interest the paper by Tugrul et al. [1] regarding
the effects of IgM-enriched immunoglobulin preparations in
patients with severe sepsis managed in their intensive care
unit. Apart from the global interest of reading a paper in the
field of the treatment of severe sepsis and septic shock, we
have an almost similar project in progress.
It is well known that the immunotherapy in sepsis is still a
gray zone, and it will remain so as long as the relevant
literature presents conflicting results [2]. From our
understanding and the interim analysis of our data, it seems
that we could expect some definitive immunotherapy
information in the near future.
In our study, we have presently included 34 patients in the
treatment group (IgM + IgG + IgA) and 34 in the control
group. Analyzing our data in a manner comparable with that
of Tugrul et al. [1], we reach a different conclusion regarding
the results.
The only difference that exists between our protocol and that
of Tugrul et al. regarding the study design and the inclusion
criteria is that we include only adults older than 18 years old
(the lower age limit of Tugrul et al.’s study is 10 years, and
adolescents are probably included).
The number of patients needed per arm of the study in order
to achieve a safe conclusion (statistical power analysis, 80%;
P < 0.05 for a mortality decrease of 17%, which was the
mortality decrease in our preliminary analysis) is 120 patients
in each arm. In a study with a smaller number of patients,
therefore, such as those of Tugrul et al. (21 patients in each
arm) or ourselves (34 patients in each arm to the present
time), any conclusion may be unsafe.
Although the data in both studies (in our opinion) are so far
not sufficient, a significant difference trend is recorded. The
mean age in Tugrul et al.’s study is 42.0 ± 18 years in the
IgM + IgG + IgA group and 49.3 ± 20.6 years in the control
group. The Acute Physiology and Chronic Health Evaluation
II (APACHE II) score in that same study is 10.5 ± 4.6 in the
IgM + IgG + IgA group and 14.0 ± 8.5 in the control group.
Although there is no statistically significant difference, there
is a strong tendency for the two means to become different
(P = 0.10).
In our preliminary data analysis, the mean age is
50.5 ± 3.33 years in the IgM + IgG + IgA group and
50.7 ± 7.36 years in the control group. The APACHE II score
in our study is 21.27 ± 7.23 in the IgM + IgG + IgA group
and 23.5 ± 7.91 in the control group.
The 28-day mortality rate in Tugrul et al.’s study is 23.8% in
the IgM + IgG + IgA group versus 33.3% in the control
group. In our preliminary data analysis, the mortality rate is
22.35% and 40.0% in the IgM + IgG + IgA group and the
control group, respectively. Although this difference is a
statistically significant one, the analysis of the mortality rate of
the subgroups according to the APACHE II scoring of
inclusion to the study day is more interesting. The mortality
rate in our preliminary data for the IgM + IgG + IgA group
with an APACHE II score ranging between 20 and 29 was
22.22%, and that of the control group with the same
APACHE II score range was 55%.
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As we pointed out earlier, in order to demonstrate the clinical
effectiveness of immunotherapy in severe sepsis and septic
shock, a number of 120 patients is necessary to be included
in each arm of our study. Using our preliminary results in the
same manner as those in Tugrul et al.’s paper [1], we could
conclude that it is sometimes possible to present the data in
such a way resulting in delusive conclusions. Analyzing the
data by means of definitions of sepsis and septic shock, and
assuming the patients to be a uniform group, we cannot
demonstrate the special subgroups of patients in whom the
administration of IgM-enriched immunoglobulin preparations
may have highly beneficial effects. By grouping the patients
according to some characteristics (such as APACHE II score
or Simplified Acute Physiology Score II score), the beneficial
effect of immunoglobulins could be shown. Using such an
approach, a beneficial effect of IgG immunotherapy in a
special subgroup of septic patients has already been shown
in the study by Dominioni et al. [3].
In conclusion, it seems that there is a subgroup of patients
with severe sepsis or septic shock in which the delivery of
IgM-enriched immunoglobulin preparations may have a
beneficial effect. Further study with more patients, either in
our study or that of Tugrul et al., is necessary before we
decide whether to use this type of immunotherapy in the
treatment of severe sepsis.
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